Mediolanum International Funds Ltd Purchases 13,809 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Mediolanum International Funds Ltd raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 30.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,902 shares of the company's stock after buying an additional 13,809 shares during the period. Mediolanum International Funds Ltd owned 0.06% of Neurocrine Biosciences worth $6,881,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. RFP Financial Group LLC raised its stake in Neurocrine Biosciences by 346.5% during the first quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after buying an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences during the second quarter worth approximately $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the second quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new position in Neurocrine Biosciences in the first quarter valued at approximately $32,000. Finally, EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter worth approximately $35,000. Institutional investors own 92.59% of the company's stock.

Insider Buying and Selling at Neurocrine Biosciences

In other news, insider Julie Cooke sold 12,632 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total value of $1,935,980.32. Following the transaction, the insider now owns 18,202 shares in the company, valued at $2,789,638.52. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Neurocrine Biosciences news, insider Julie Cooke sold 12,632 shares of Neurocrine Biosciences stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the transaction, the insider now owns 18,202 shares of the company's stock, valued at $2,789,638.52. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ingrid Delaet sold 273 shares of Neurocrine Biosciences stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the transaction, the insider now owns 6,607 shares in the company, valued at approximately $975,853.90. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,968 shares of company stock worth $8,999,632. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences Trading Up 0.5 %

Shares of NASDAQ:NBIX traded up $0.56 during trading on Friday, reaching $116.08. 1,009,703 shares of the company traded hands, compared to its average volume of 849,443. Neurocrine Biosciences, Inc. has a 52-week low of $103.63 and a 52-week high of $157.98. The business's fifty day moving average is $122.86 and its 200-day moving average is $134.01. The firm has a market capitalization of $11.72 billion, a price-to-earnings ratio of 35.07 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business had revenue of $590.20 million during the quarter, compared to the consensus estimate of $545.98 million. During the same period in the previous year, the business earned $0.95 earnings per share. The firm's revenue for the quarter was up 30.4% compared to the same quarter last year. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NBIX has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $190.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Piper Sandler upgraded Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and boosted their price objective for the company from $131.00 to $159.00 in a report on Thursday, August 29th. Guggenheim boosted their price target on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. Robert W. Baird raised their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Finally, Citigroup upped their target price on shares of Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a "neutral" rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.